Related Experiment Video
Updated: Jun 25, 2025
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
The Biological Impact of Some Phosphonic and Phosphinic Acid Derivatives on Human Osteosarcoma
Zakzak Khaled1,2, Gheorghe Ilia3, Claudia Watz4,5
1Pharmaceutical Technology, Faculty of Pharmacy, "Victor Babeş" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
Abstract:
Osteosarcoma malignancy currently represents a major health problem; therefore, the need for new therapy approaches is of great interest. In this regard, the current study aims to evaluate the anti-neoplastic potential of a newly developed phosphinic acid derivative (2-carboxyethylphenylphosphinic acid) and, subsequently, to outline its pharmaco-toxicological profile by employing two different in vitro human cell cultures (keratinocytes-HaCaT-and osteosarcoma SAOS-2 cells), employing different techniques (MTT assay, cell morphology assessment, LDH assay, Hoechst staining and RT-PCR). Additionally, the results obtained are compared with three commercially available phosphorus-containing compounds (P1, P2, P3). The results recorded for the newly developed compound (P4) revealed good biocompatibility (cell viability of 77%) when concentrations up to 5 mM were used on HaCaT cells for 24 h. Also, the HaCaT cultures showed no significant morphological alterations or gene modulation, thus achieving a biosafety profile even superior to some of the commercial products tested herein. Moreover, in terms of anti-osteosarcoma activity, 2-carboxyethylphenylphosphinic acid expressed promising activity on SAOS-2 monolayers, the cells showing viability of only 55%, as well as apoptosis features and important gene expression modulation, especially Bid downregulation. Therefore, the newly developed compound should be considered a promising candidate for further in vitro and in vivo research related to osteosarcoma therapy.
Insights
A new phosphinic acid derivative shows promise for osteosarcoma therapy. It demonstrated good biocompatibility in normal cells and significant anti-cancer activity in osteosarcoma cells, warranting further research.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Osteosarcoma presents a significant health challenge, driving the search for novel therapeutic strategies.
- Developing new anti-cancer agents with favorable safety profiles is crucial for effective treatment.
Purpose of the Study:
- To evaluate the anti-neoplastic potential and pharmaco-toxicological profile of a novel phosphinic acid derivative, 2-carboxyethylphenylphosphinic acid (P4).
- To compare the efficacy and safety of P4 against existing phosphorus-containing compounds (P1, P2, P3).
Main Methods:
- In vitro studies using human keratinocyte (HaCaT) and osteosarcoma (SAOS-2) cell lines.
- Assays included MTT, cell morphology, LDH release, Hoechst staining, and RT-PCR to assess viability, toxicity, apoptosis, and gene expression.
Main Results:
- Compound P4 exhibited good biocompatibility on HaCaT cells (77% viability at 5 mM) with no significant morphological or gene expression changes.
- P4 demonstrated promising anti-osteosarcoma activity on SAOS-2 cells (55% viability), inducing apoptosis and modulating gene expression, notably downregulating Bid.
- P4's biosafety profile was superior to some commercial compounds tested.
Conclusions:
- 2-carboxyethylphenylphosphinic acid is a promising candidate for further investigation in osteosarcoma therapy.
- The compound's dual action of safety in normal cells and efficacy against cancer cells supports its therapeutic potential.
